

antiviral and associated therapy - all results

Treatment	Number of studies	Demonstrated or suggested results	Inconclusive results	Uncertain results	Safety results
ivermectin	11 studies ¹		inconclusive results for : Emergency room visit or hospitalization ; deaths ; hospitalization or death ; clinical deterioration ; clinical improvement ; clinical improvement (21-day) ; clinical improvement (28-day) ; clinical improvement (time to event analysis only) ; hospitalization ; mechanical ventilation ; Recovery (time to event analysis only) ; viral clearance ; viral clearance by day 14 ; viral clearance by day 7 ; serious adverse events ; adverse events		
chloroquine and derivatives	8 studies ²		inconclusive results for : deaths ; clinical deterioration ; clinical improvement ; clinical improvement (14-day) ; hospitalization ; mechanical ventilation ; viral clearance ; viral clearance by day 14 ; viral clearance by day 7 ; ICU admission ; adverse events		
azithromycin	4 studies ³		inconclusive results for : deaths ; hospitalization or death ; A EFFACER PCR-negative (end of follow-up) ; clinical improvement ; clinical improvement (14-day) ; clinical improvement (time to event analysis only) ; hospitalization ; mechanical ventilation ; ICU admission	suggested 715.0-fold increase in viral clearance but the degree if certainty is unassessable	

Continued on next page

Treatment	Number of studies	Demonstrated or suggested results	Inconclusive results	Uncertain results	Safety results
fluvoxamine	4 studies ⁴	demonstrated 28			
hydroxychloroquine plus macrolides	2 studies ⁵		inconclusive results for : deaths ; clinical improvement ; hospitalization ; viral clearance ; viral clearance by day 14 ; viral clearance by day 7		
molnupiravir	2 studies ⁶	suggested 90			
lopinavir/ritonavir	1 study ⁷		inconclusive results for : deaths ; hospitalization ; viral clearance ; viral clearance by day 14		
nirmatrelvir / ritonavir (Paxlovid)	1 study ⁸		inconclusive results for : related AE (TRAE) ; related SAE (TRSAE)	suggested 96	
nitazoxanide	1 study ⁹		-		
remdesivir	1 study ¹⁰		inconclusive results for : death D28 ; deaths ; AE leading to drug discontinuation ; adverse events	demonstrated 87	
sofosbuvir and daclatasvir	1 study ¹¹		inconclusive results for : hospitalization		
zinc	1 study ¹²		-		

Uncertain results are statistically significant results but obtain in trial with high risk of bias.

Demonstrated results are significant results obtained on the primary endpoint of a trial at low risk of bias or with some concerns.

Notes

¹ACTIV-6 (ivermectine), 2023 (NCT04885530); ACTIV 6 ivermectin, 2022 (NCT04885530); COVID-OUT (ivermectin), 2022 (NCT04510194); TOGETHER (ivermectine), 2022 (NCT04727424); Lopez-Medina, 2021 (NCT04405843); Chaccour, 2020 (NCT04390022); Chowdhury A, 2020 (NCT04434144); IVERCORCOVID19 (Vallejos), 2020 (NCT04529525); Podder, 2020 (); Chahla, 2021 (NCT04784481); Espitia-Hernandez, 2020 ()

²COPE – Coalition V, 2022 (NCT04466540); PATCH Cohort 1 (Amaravadi), 2021 (NCT04329923); Reis (Hydroxychloroquine) (TOGETHER), 2021 (NCT04403100); BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020 (NCT04304053); COMIHY, 2020 (NCT04340544); COVID-PEP Severity (Skipper), 2020 (NCT04308668); Q-PROTECT -HCQ alone, 2020 (NCT04349592); Agusti, 2020 ()

³ACTION, 2021 (NCT04332107); Hinks (ATOMIC2), 2021 (NCT04381962); PRINCIPLE, 2021 (ISRCTN86534580); Espitia-Hernandez, 2020 ()

⁴ACTIV-6, 2022 (NCT04885530); COVID-OUT (fluvoxamine), 2022 (NCT04510194); TOGETHER, 2021 (NCT04727424); Lenze (STOP COVID 1), 2020 (NCT04342663)

⁵Rodrigues, 2021 (); Q-PROTECT (HCQ/AZI vs PLACEBO), 2020 (NCT04349592)

⁶Fischer (all doses), 2021 (NCT04405570); MOVE-OUT, 2021 (NCT04575597)

⁷Reis (Lopinavir-ritonavir) (TOGETHER), 2021 (NCT04403100)

⁸EPIC-HR, 2021 (NCT04960202)

⁹RM08-3008 (Rossignol), 2021 (NCT04486313)

¹⁰PINETREE (GS-US-540-9012), 2021 (NCT04501952)

¹¹Roosbeh, 2020 (IRCT20200403046926N1)

¹²Thomas (zinc only), 2021 (NCT04342728)